Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG - Trial NCT06378021
Access comprehensive clinical trial information for NCT06378021 through Pure Global AI's free database. This Phase 3 trial is sponsored by Helwan University and is currently Recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Helwan University
Timeline & Enrollment
Phase 3
Mar 14, 2024
Apr 01, 2025
Primary Outcome
Change in number of patients who developed Atrial fibrillation
Summary
This study hypothesize that injecting calcium chloride (CaCl2) into the major atrial
 ganglionated plexus (GPs) during on pump Coronary artery bypass graft (CABG) can reduce the
 incidence of Post operative Atrial fibrillation in the first 7 days after surgery.The study
 is designed to be prospective interventional study two armed RCT for on pump CABG patient.
 
 The intervention arm will be injected with Calcium chloride in the four major atrial
 ganglionic plexus The control arm will be injected with sodium chloride to determine the
 effect of Calcium chloride on Post CABG Atrial fibrillation
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06378021
Non-Device Trial